Fujifilm Receives PACS Award for Naval Medical Center - San Diego

Lexington, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, today announced that the company was selected to transform the enterprise radiology PACS at the Naval Medical Center - San Diego with Synapse® 7x – Fujifilm’s next-generation enterprise imaging platform. 

Synapse 7x unites data and imaging from radiology, mammography, cardiology, 3D and other enterprise imaging solutions on server-side rendering technology. Synapse 7x was recently granted a Risk Management Framework (RMF) and Authority to Operate (ATO) on U.S. Department of Defense (DoD) networks. With Synapse 7x, organizations within the DoD network – now including Naval Medical Center - San Diego - will be able to access the diagnostic PACS platform that extends across the enterprise, an evolution from a radiology-specific PACS platform.

This award includes Navy Medical Center San Diego, Camp Pembleton, 29 Palms, Lemoore, plus approximately 40 additional medical treatment facilities will consolidate PACS vendors to have Fujifilm become the sole provider, streamlining patient imaging and data across the entire network.

“We’re honored to continue to further expand our engagement with the U.S. Department of Defense and to support the prestigious Naval Medical Center - San Diego’s effort to enhance clinical collaboration and military patient care across southern California,” says Bill Lacy, senior vice president, medical informatics, FUJIFILM Healthcare Americas Corporation. “We believe this award reflects our continued commitment to deliver the informatics technology innovation and security compliance the DOD demands of its partners.”

To learn more about Fujifilm’s Synapse® Enterprise Imaging portfolio, click here. 

About Fujifilm

FUJIFILM Healthcare Americas Corporation is a comprehensive healthcare company that has an extensive range of technology and expertise in the detection, diagnosis and treatment of diseases. Fujifilm’s innovative medical imaging portfolio includes solutions for digital radiography, mammography, CT, MRI, ultrasound, gastroenterology, pulmonology, endosurgery, and minimally invasive surgery. The award-winning Synapse® Enterprise Imaging portfolio provides healthcare professionals with the cross-departmental imaging and data access needed to deliver a complete patient record. Fujifilm’s AI initiative, REiLI®, combines Fujifilm’s rich image-processing heritage with cutting-edge innovations to inspire clinical confidence and combat burnout. The In-Vitro Diagnostic portfolio provides the gold standard of molecular based immunoassay technology for liver surveillance, cutting edge clinical diagnostic chemicals for leading laboratories and diagnostic chemicals for OEM white labelling products. The company is headquartered in Lexington, Massachusetts. Click here for more information.

FUJIFILM Holdings Corporation, Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver “Value from Innovation” in our products and services in the business segments of healthcare, materials, business innovation, and imaging. Our relentless pursuit of innovation is focused on providing social value and enhancing the lives of people worldwide. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information about Fujifilm’s Sustainable Value Plan 2030, click here. For the year ended March 31, 2023, the company had global revenues of approximately 2.9 trillion yen (21 billion USD at an exchange rate of 134 yen/dollar). For more information, please visit: www.fujifilmholdings.com.

Marissa Confredo
FUJIFILM Holdings America Corporation
914-343-4761
[email protected]